Intended for healthcare professionals

  1. News & Views
  2. Rosiglitazone: what...
  3. Rosiglitazone: what went wrong?
Feature Drug Regulation

Rosiglitazone: what went wrong?

BMJ 2010; 341 doi: https://doi.org/10.1136/bmj.c4848 (Published 06 September 2010) Cite this as: BMJ 2010;341:c4848

Related articles

See more

Cited by...

  • Updating Insights into Rosiglitazone and Cardiovascular Risk through Shared Data: Individual Patient- and Summary-Level Meta-Analyses
  • Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses
  • Commercial interests, transparency, and independence: a call for submissions
  • Sex and BMI Alter the Benefits and Risks of Sulfonylureas and Thiazolidinediones in Type 2 Diabetes: A Framework for Evaluating Stratification Using Routine Clinical and Individual Trial Data
  • Rethinking the appraisal and approval of drugs for type 2 diabetes
  • Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation
  • A comparison of adverse event and fracture efficacy data for strontium ranelate in regulatory documents and the publication record
  • Guidelines: is bigger better? A review of SIGN guidelines
  • FDA official: "clinical trial system is broken"
  • Which is the best research paper of all time?
  • Big pharma often commits corporate crime, and this must be stopped
  • Withdraw approval for Tamiflu until NICE has full data
  • FDA raises concerns about ultra-long acting insulins given green light in Europe and Japan
  • Clinical trial data for all drugs in current use
  • Metformin Prevents the Development of Chronic Heart Failure in the SHHF Rat Model
  • Ensuring safe and effective drugs: who can do what it takes?
  • Independent public inquiries needed to ensure drug safety
  • Data availability for industry sponsored trials: what should medical journals require?
  • Missing clinical trial data: setting the record straight
Back to top